MARKET INTELLIGENCE · PUBLISHED JUNE 2026 · UKMC GROUP LTD
Primary source market data for investors, family offices and professional advisers — covering the UK medical cannabis market, key global patient markets, supply chain dynamics and the regulatory landscape shaping investment returns in 2026 and 2027.
This page is published for informational purposes only and does not constitute financial, investment, legal or tax advice. All data is sourced from primary regulatory and government sources unless otherwise stated. Readers should seek independent professional advice before making any investment decision.
The global medical cannabis market is no longer a frontier sector. It is a functioning, regulated pharmaceutical and healthcare industry — operating across multiple continents, supplied by an international supply chain, governed by national regulatory frameworks and attracting sustained capital from private equity, venture capital, family offices and institutional investors.
In 2025 and into 2026, global medical cannabis markets expanded significantly and unevenly — shaped by regulatory design, telemedicine access, domestic production rules and prescribing capacity. Canada consolidated its position as the dominant global supplier. Germany became the largest European patient market by significant margin. Australia became the second largest globally outside North America. And the United Kingdom — despite operating within a comparatively tight regulatory environment — grew its market by 103% year-on-year, establishing itself as one of the most strategically significant emerging patient markets in Europe.
This page provides primary source market intelligence for investors, family offices, private wealth owners and professional advisers seeking to understand the scale, structure and trajectory of the UK and global medical cannabis market in 2026.
All data on this page is sourced from the Global Medical Cannabis Market Review 2026 published by Prohibition Partners, drawing on primary data from Statistics Canada, Health Canada, the International Narcotics Control Board (INCB), Germany's Federal Institute for Drugs and Medical Devices (BfArM), the UK Home Office, the Australian Office of Drug Control (ODC), the Israeli Ministry of Health, the Polish Centrum e-Zdrowia and multiple other national regulatory bodies.
UK medical cannabis market size in 2025 (US $298 million). Source: Prohibition Partners Global Medical Cannabis Market Review 2026.
Year-on-year market growth in 2025. The UK medical cannabis market more than doubled in a single year. Source: Prohibition Partners 2026.
Estimated active UK medical cannabis patients in 2025. Source: Prohibition Partners 2026.
Unique product SKUs available to UK patients in 2025, with average flower price of £7.05 per gram. Source: MedBud.wiki and Prohibition Partners 2026.
The UK medical cannabis market operates within a relatively tight regulatory environment compared to Germany or Australia. This has resulted in a total number of prescribing doctors in the low hundreds, a high administrative burden for suppliers and a high cost of treatment for patients — involving peer review sessions and repeat prescription consultations that create significant friction in the patient journey.
Despite these structural constraints, market growth has been substantial. The UK's 103% year-on-year growth in 2025 reflects the combination of increasing clinician confidence, expanding telehealth clinic networks and growing patient awareness. As of 2025, 99.5% of medical cannabis prescriptions in the UK were issued in independent private healthcare settings, with telemedicine consultations playing a central role.
The top five UK medical cannabis teleclinics collectively attracted 1.1 million website visits in October 2025 alone — led by Releaf (535,400 visits), Curaleaf Clinics (301,138), Alternaleaf (157,008), Lyphe (74,822) and Mamedica (60,474). These five platforms serve the majority of the current UK patient population.
The United Kingdom is almost entirely dependent on imported medical cannabis. In 2024, imports accounted for 96.9% of UK medical cannabis supply, with domestic cultivation representing only 3.1% of total volume. This import dependency is a fundamental structural characteristic of the UK market and a key consideration for investors evaluating the supply chain.
The primary sources of UK medical cannabis imports are Portugal, Canada and Spain. Portugal has emerged as the largest single source of European medical cannabis exports — with 2024 export volumes approximately triple those of the next-largest European exporter, Denmark — though a significant proportion of Portuguese exports are understood to derive from Canadian cultivation imported and processed in Portugal before re-export.
In June 2025, the UK government commissioned the Advisory Council on the Misuse of Drugs (ACMD) to conduct a formal review of the legal framework for prescribing Cannabis-Based Products for Medicinal Use (CBPMs). Between September and October 2025, the ACMD launched a call for evidence from medical cannabis stakeholders.
The UK's Care Quality Commission (CQC) also published its annual report on the Safer Management of Controlled Drugs in July 2025, raising significant concerns about the rapid increase in medical cannabis prescriptions — noting a 130% rise in prescriptions dispensed by private clinics between 2023 and 2024. The CQC cited concerns about the prescribing of cannabis for conditions lacking strong clinical evidence and inappropriate advertising practices.
The outcome of the ACMD review — which can take up to a year or longer — will be the single most important regulatory development shaping the UK medical cannabis investment environment in 2026 and 2027. Investors should monitor its progress closely.
"The UK medical cannabis market grew 103% year-on-year in 2025, reaching £226 million in market value — with 90,000 to 94,000 active patients and 628 unique product SKUs available. Despite operating within a tight regulatory environment, the UK is now the third-largest medical cannabis patient market in Europe."
Germany is the largest medical cannabis patient market in Europe and the second largest globally outside North America. Growth of 155% year-on-year in 2025 was driven by the implementation of the Cannabis Act (CanG) on 1 April 2024, which removed medical cannabis from the German Narcotic Drugs Act and simplified prescribing. The German market is now under significant regulatory scrutiny, with proposed restrictions on telemedicine and mail-order pharmacy delivery currently working through the Bundestag.
Source: Prohibition Partners Global Medical Cannabis Market Review 2026, BfArM, INCB.
Australia is the second largest medical cannabis market globally outside North America, with a 2025 market size exceeding AUD $1 billion. The market is dominated by vertically integrated telemedicine platforms. Over 45 teleclinics are active, with the market leader Alternaleaf/Montu attracting 212,959 website visits in October 2025 alone. The market faces regulatory scrutiny from the TGA regarding prescribing oversight and advertising practices.
Source: Prohibition Partners Global Medical Cannabis Market Review 2026, Australian Office of Drug Control 2025.
The UK is the third largest medical cannabis patient market in Europe, growing 103% year-on-year in 2025. The market operates through private prescription only, with NHS coverage almost non-existent. The CQC ACMD review and telemedicine scrutiny represent the primary regulatory risks. The UK's tight regulatory environment has paradoxically created a more clinically rigorous and defensible market than Germany or Australia — which may prove advantageous if international regulatory scrutiny of looser markets intensifies.
Source: Prohibition Partners Global Medical Cannabis Market Review 2026, Home Office, MedBud.wiki.
Poland's market contracted 18% in 2025 following telemedicine restrictions implemented in November 2024, which required initial consultations to be conducted in person. Prescription numbers declined 54% from October to December 2024. However, the market showed early signs of recovery in Q1 2025, driven by the establishment of hybrid medical cannabis clinics combining permanent city locations with mobile rural outreach. Poland serves as the most instructive global case study for the impact of telemedicine restrictions — directly relevant to investors monitoring regulatory developments in the UK and Germany.
Source: Prohibition Partners Global Medical Cannabis Market Review 2026, Centrum e-Zdrowia 2025.
Brazil is one of the world's largest medical cannabis patient populations by number, though access to affordable treatment remains limited. New regulations passed in early 2026 by ANVISA have established three cultivation pathways and expanded approved administration routes, paving the way for significant market expansion. International suppliers face complex partnership requirements to access the market.
Source: Prohibition Partners Global Medical Cannabis Market Review 2026, ANVISA 2026.
France is the largest prospective medical cannabis market in Europe that has not yet reached commercial scale. Its pilot programme began in March 2021 and has been extended while a permanent regulatory framework is finalised. In February 2026, French authorities confirmed a timetable targeting core decrees by end of June 2026. Standard prescribing under common law is not expected before 2027. With the second-largest population in the EU and a strong healthcare infrastructure, France represents a significant future market opportunity — though the reimbursement structure and prescribing pathway will determine the commercial scale.
Source: Prohibition Partners Global Medical Cannabis Market Review 2026, ANSM 2025.
Canadian medical cannabis exports in 2025. More than 2.5 times the 2024 volume of 107,632kg. Source: Statistics Canada, Prohibition Partners 2026.
Canada's 2024 cultivation volume plus 2025 start-of-year stock is approximately eight times the maximum cultivation estimates of the rest of the world combined in 2025. Source: Health Canada, INCB, Prohibition Partners 2026.
Approximate global cannabis surplus in the supply chain in 2025 — almost exactly equivalent to the stock held by Canadian operators at the start of the year. Source: Health Canada, Statistics Canada, INCB, Prohibition Partners 2026.
In the international medical cannabis supply chain, Canada is the superpower. Canadian annual export volumes reached over 275 tonnes in 2025 — more than 2.5 times the 2024 volume of 107 tonnes — representing a marked acceleration in the pace of export growth.
Canadian producers have a quantitative and qualitative advantage over international competitors. Due to over two decades of medical cannabis production, the Canadian industry has developed superior cultivation and manufacturing techniques, research and innovation in genetics and processing, and the benefits of an industrial cluster — deep talent pools, knowledge spillover and dense supplier networks. Canadian medical cannabis is often available at a lower price and at a higher level of consistent quality than competing international products.
For UK investors in clinical networks, importers and distributors, this supply dynamic has critical implications. Price compression from abundant Canadian supply is a real and present commercial risk for operators whose margin depends on premium product pricing. However, the same dynamic creates opportunity: well-capitalised UK importers and distributors with established supply relationships and MHRA-compliant frameworks are positioned to benefit from reliable, competitively priced Canadian supply as UK patient volumes grow.
Portugal is the largest European exporter of medical cannabis, with 2024 export volumes of 31,021kg — approximately triple those of the next-largest European exporter, Denmark, at 9,747kg. However, a significant and growing proportion of Portuguese exports derive from Canadian cultivation imported and processed in Portugal before re-export. The quantity of dried flower exported from Canada to Portugal rose from 1.5 tonnes in 2023 to 17.5 tonnes in 2024, and reached 39 tonnes in the first eight months of 2025 alone. Portugal is increasingly a processing and re-exportation hub rather than a primary cultivator — a structural shift with significant implications for the economics of European supply chains.
Source: Infarmed, Statistics Canada (StatCan), Prohibition Partners 2026.
Telemedicine has become the backbone of medical cannabis access in most major markets — and the single most significant regulatory risk factor for investors in 2026 and 2027.
47 identified medical cannabis teleclinics. Top 5 clinics: 485,103 combined website visits in October 2025. Market size: AUD $1 billion+.
35 identified medical cannabis teleclinics. Top 5 clinics: 4.2 million combined website visits in October 2025. Market growing at 155% year-on-year.
29 identified medical cannabis teleclinics. Top 5 clinics: 1.1 million combined website visits in October 2025. Market growing at 103% year-on-year.
23 identified medical cannabis teleclinics. 159,570 combined visits (top 5, October 2025). Market growing at 47% year-on-year.
Prescriptions declined 54% within two months of telemedicine restrictions being introduced in November 2024 — before recovering as hybrid clinic models emerged.
Source: Prohibition Partners 2025, SimilarWeb 2025, Centrum e-Zdrowia 2025.
Poland provides the clearest available evidence of what happens when telemedicine restrictions are introduced into a functioning medical cannabis market. Following the Polish Ministry of Health's November 2024 regulations requiring initial consultations to be conducted in person, prescription numbers declined 54% from October to December 2024. Patient numbers fell from a peak of over 137,000 in 2024 to roughly 93,000 in September 2025.
However, the recovery was faster than anticipated. Specialised hybrid medical cannabis clinics — with permanent city locations and mobile rural outreach — enabled the market to begin recovering in Q1 2025. By September 2025, total dispensed volume exceeded 3.5 million grams — a 47% increase over 2023 volumes, though 25% below 2024.
Germany's proposed telemedicine restrictions — currently working through the Bundestag as of early 2026 — represent the most significant single regulatory risk event in the global medical cannabis market in 2026 and 2027. Prohibition Partners has modelled three scenarios:
Minimal regulatory change. Market continues on current growth trajectory. Germany reaches €1.5 billion+ market size by 2028–2029.
Teleclinics must conduct video consultations rather than questionnaire-only assessments. Prohibition Partners projects a 25% decline in market size in 2026, with patient numbers falling from approximately 700,000 to 560,000 — before recovering at a monthly growth rate modelled on the UK's 2.4% expansion rate from 2027 onwards.
Mandatory in-person initial consultations and ban on mail-order pharmacies. Market projects to lose approximately 50% of patients over five months — from 700,000 to 430,000 — before partial recovery at 40% of the Scenario 2 growth rate. Significant pharmacy closures expected, supply surplus intensifies, operator consolidation accelerates.
Source: Prohibition Partners Global Medical Cannabis Market Review 2026. Scenario modelling is for informational purposes only and does not constitute investment advice.
The global market data presented in this report points to five clear investment implications for UK family offices, private wealth owners and professional investors considering medical cannabis allocation in 2026:
At 103% year-on-year growth in 2025, the UK medical cannabis market is one of the fastest growing regulated healthcare markets in Britain. The market reached £226 million in 2025 with 90,000 to 94,000 patients — but penetration remains extremely low at approximately 0.1–0.2% of the UK population. Comparable markets like Germany and Australia have reached 1–2% patient penetration. The growth runway for the UK market is substantial if regulatory conditions remain stable.
The ACMD review, CQC scrutiny and the Poland and Germany precedents all point to telemedicine regulation as the primary near-term risk factor for UK cannabis operators and their investors. The Poland case study demonstrates both the severity of the short-term impact and the speed of recovery when hybrid clinic models emerge. UK investors should stress-test their investment thesis against both a restriction scenario and a no-restriction scenario.
With approximately 1.8 million kilograms of surplus cannabis in the global supply chain — almost entirely attributable to Canadian stock — price compression on medical cannabis flower is structural, not cyclical. UK importers and distributors competing on product pricing alone face margin pressure. The investment thesis for UK supply chain businesses must be built on compliance infrastructure, relationship depth and operational efficiency rather than premium product pricing.
The UK's comparatively restrictive regulatory environment — requiring peer review, in-person elements and clinical justification — has created a more defensible market than Germany or Australia. If looser markets face significant regulatory intervention, the UK model may emerge as the template for sustainable medical cannabis healthcare delivery. Investors who understand the regulatory architecture are better positioned to identify which UK operators are built for the long term.
Germany's telemedicine restriction decision — expected in spring 2026 — will have direct implications for UK investment valuations, supply chain economics and the appetite of international capital for European cannabis assets. UK investors with European exposure or who are evaluating entry should monitor the Bundestag process as a leading indicator for the direction of travel across the continent.
All market data, statistics and regulatory information on this page is sourced from the following primary and secondary sources:
THE SUMMIT
The UK Medical Cannabis Investment Summit 2027 is the senior two-day closed forum bringing together the investors, family offices, private wealth owners, fund managers, clinicians, policymakers and industry leaders defining the future of UK medical cannabis — in London, in June 2027.
The Summit programme covers market intelligence, regulatory developments, investment strategy, clinical evidence and the global context shaping UK medical cannabis in 2027 — designed to bring every attendee, from the newly curious family office to the experienced operator, to the same informed level before the day's dialogue begins.
Early bird delegate passes: £595 + VAT until 10 January 2027. Full rate: £995 + VAT from 11 January 2027.
IMPORTANT NOTICE
This page is published by UKMC Group Ltd for informational and educational purposes only. Nothing on this page constitutes financial advice, investment advice, legal advice, tax advice or any other form of regulated professional advice.
All market data, statistics and regulatory information is sourced from the Prohibition Partners Global Medical Cannabis Market Review 2026 and the primary regulatory data sources cited above, and was accurate to the best of our knowledge as published in that report. Readers should verify current information independently as market and regulatory conditions change rapidly.
Medical cannabis investment carries significant risks. Readers should seek independent financial, legal and tax advice from appropriately qualified and regulated professionals before making any investment decision. UKMC Group Ltd is not a regulated financial adviser and does not provide regulated investment services.
© 2026 UKMC Group Ltd. All rights reserved.